Exhibit at RESI Boston

July 7, 2022 ~ Next Phase Admin ~ Leave a comment

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

RESI returns to Boston for its first in-person conference in over two years September 21-22, with an additional day of virtual partnering on September 23. Past in-person RESIs boasted a vibrant network of service providers, including CRO/CMOs, non-profits, suppliers, and professional services like law firms and banks. These service providers have played an essential role in the RESI ecosystem, and we are pleased to welcome them back with more offerings that include both onsite and digital formats to promote their services and connect them with early-stage startups who need them.

RESI’s unique value to its service providers is its dedication to early-stage companies in life science and healthcare. These startups have specific needs that make them ideal clients for a variety of providers. CRO/CMOs attend RESI to connect with preclinical therapeutics. Lab services with valuable R&D space, banks with life science-specific benefits, and law firms specializing in IP, term sheet negotiations, and more exhibit at RESI to connect with these founders who seek their services.

RESI exhibition includes a table for promotion and networking in the exhibit hall, as well as a dedicated webpage for additional marketing materials and connections with virtual attendees. Exhibitors also have their logo featured prominently on the RESI website, live agenda, program guide, and onsite signage. For $4K, the exhibitor package also includes a complimentary registration to participate in the partnering platform and attend all conference events. Interested in reaching a broad audience of early-stage entrepreneurs at RESI Boston? Check out our sponsorship brochure and contact us to learn more!

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International	East Coast (USA) & China	Midwest (USA) & Canada	West Coast (USA)

Greg Mannix Vice President International Business Development Book a Meeting Email Me	Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Alexander Vassallo Manager of Business Development, Entrepreneurial Education Lead Book a Meeting Email Me

Summer of Savings Continues

July 7, 2022 ~ Next Phase Admin ~ Leave a comment

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

The summer of savings continues with RESI Boston’s early bird rates available until July 29. RESI returns to Boston September 21-22, with an additional day of dedicated virtual partnering September 23. RESI attracts early-stage founders and CEOs of life science and healthcare startups seeking capital and licensing partners. These attendees are actively seeking funding, therefore, creating a valuable experience at an affordable rate is essential to their enthusiastic participation in RESI’s vibrant partnering and networking format.

Startups can save $300 with early bird rates when they register by July 29. Additionally, free webinars to enhance partnering and pitching, as well as how to make the most of the RESI experience are available throughout the summer. Sign up for a free webinar below and register for RESI Boston today and save!

July 7 | 2 PM EDT – Maximizing the Power of Your Pitch

Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.

REGISTER HERE

July 13 | 12 PM EDT – Fundraising Bootcamp: It All Starts with the Story

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.

REGISTER HERE

July 20 | 1 PM EDT – Supporting Tech Hub Startups at RESI

This workshop is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startup constituents who’ve raised less than $2M expand outreach from Regional to Global, build a target list of investors, and more.

REGISTER HERE

July 26 | 11 AM EDT – Fundraising Bootcamp: Branding Your Company from Seed to Series B

Many companies have great science and a compelling project to tell investors about, but don’t have the right tools to communicate effectively. What are the elements of marketing collateral needed to efficiently fundraise in the early stages? This webinar will dive into this important subject and help you to build a powerful marketing collateral for your fundraise.

REGISTER HERE

August 3 | 11 AM EDT – Maximizing the Power of Your Pitch

REGISTER HERE

August 17 | 1 PM EDT – Keys to Successful Partnering

Partnering events like the RESI conference series are a fundamental part of fundraising. They present a great opportunity to meet new potential investors and strategic partners but getting the meetings you want is competitive and difficult. What strategies have proven successful to get the most meetings? What can you do to stand out and have a better chance of catching the attention of investors? This webinar will address these and other important aspects of partnering.

REGISTER HERE

Hot Investor Mandate: Large Healthcare Company Invests Up to $10M in North America or China-Based Life Science Companies in Oncology, CNS, Women’s Health, and More

July 7, 2022 ~ Next Phase Admin ~ Leave a comment

A fully integrated healthcare solution provider headquartered in China is leading in several market segments in Asia, including family planning medicines, anesthesia, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Strategic Corporate VC Fund Invests in Early-Stage Therapeutics and Drug Discovery Technologies With Strongest Interest in Oncology

July 7, 2022 ~ Next Phase Admin ~ Leave a comment

A strategic corporate venture capital fund of an oncology pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the corporate’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the corporate’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Investment Firm Allocates $20-50M in Novel Drug Discovery and Development Companies, Considering Opportunities in the Earliest Stages of Development

July 7, 2022 ~ Next Phase Admin ~ Leave a comment

A firm based in USA actively makes equity investments in early stage biotechnology companies with typical allocations of about $20-50M per company. The firm will consider investing in researchers located worldwide but typically create companies anywhere in the US where there is strong biology/biotech talent, inclusive but not limited to San Francisco, San Diego, Seattle, Dallas, NY, and Boston. The firm would only build/invest in a company elsewhere in exceptional circumstances. The firm only considers opportunities in which they can participate in the first round of institutional investment.

The firm is seeking to build drug discovery and development companies, and prefers to invest at or before the preclinical stage; the firm is open to investing in concept-stage technologies that do not yet have protected IP. The firm focuses on novel biology; the firm will consider investments in any disease area and is open to investing in any therapeutic technology provided the potential application of the technology has been established. Only therapeutic technologies are of interest; devices and diagnostics will not be considered.

The firm typically engages prior to company formation. The firm is a very hands-on investor and will take an active role in management recruitment and company-building.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm With Diverse Interests Seeks Software-Based Technologies, Medical Devices, Diagnostics Across the Globe, Preferring Companies Beyond Very Early Stage

July 7, 2022 ~ Next Phase Admin ~ Leave a comment

An equity investment firm with an investment bank has an active investment strategy that promotes company development (operations, sales, partnerships, etc.). The firm considers a broad range of sectors, including life science and healthcare with a particular interest in software and consumer products. The firm typically leads investments but does not invest in startups. The firm invests on a global level, and seeks companies based all over the world.

The firm is open to all opportunities in healthcare IT, diagnostics, medical devices of all classes, and laboratory equipment. The firm is particularly interested in technology involving software, though is not open to biotech therapeutics because of the longer timeline to commercialization. However, the firm is very interested in (nuclear) radiopharmaceuticals. The firm is interested in late-stage companies that are generating revenue with positive cash-flow.

The firm will typically provide guidance and leadership support after an investment, and would support the company with future endeavors, including joint ventures and licensing partnerships. The firm would take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Longevity Mandate: China-Based Corporation

July 6, 2022 ~ Next Phase Admin ~ Leave a comment

The firm is a fully integrated healthcare solution provider that was founded in 1993 and is headquartered in Wuhan, China. The firm is leading in several market segments in Asia, including family planning medicines, anesthesia, Uyghur medicines, traditional Chinese medicines, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.